CFMS - Conformis, Inc.
Chart Events
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 0.8989 |
| Open | 0.9300 |
| Bid | 0.8623 x 800 |
| Ask | 0.9400 x 1100 |
| Day's Range | 0.8625 - 0.9400 |
| 52 Week Range | 0.5000 - 4.8300 |
| Volume | 720,613 |
| Avg. Volume | 558,095 |
| Market Cap | 64.472M |
| Beta (5Y Monthly) | 2.14 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4640 |
| Earnings Date | May 11, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.33 |
- GlobeNewswire
Conformis Announces Settlement of Patent Dispute
BILLERICA, Mass., May 28, 2020 -- Conformis, Inc. (NASDAQ:CFMS) announced today that it has entered into a settlement and license agreement with Zimmer Biomet Holdings, Inc.,.
- GlobeNewswire
Prestigious Klee Family Foundation Prize 2020 Awarded for Outstanding Scientific Work Identifying Patient-Specific Approach as Better Way to Optimize Knee Implant Design
Conformis, Inc. (CFMS) congratulates Dr. Malte Asseln for winning the prestigious Klee Prize 2020 for his dissertation and computer-and-image-based workflow on the optimization of knee implant design - “Morphological and Functional Analysis of the Knee Joint for Implant Design Optimization.” As reported in Medizin and Technik on May 6, 2020, Dr. Asseln’s results show that more knee implant sizes are required than are currently manufactured by off-the-shelf knee implant manufacturers, so patient-specific or better-tailored solutions are a promising approach to increase the 70 percent industry-wide patient satisfaction with artificial knee joints that he has observed.
- Thomson Reuters StreetEvents
Edited Transcript of CFMS earnings conference call or presentation 11-May-20 8:30pm GMT
Q1 2020 Conformis Inc Earnings Call
- Zacks
ConforMIS (CFMS) Reports Q1 Loss, Lags Revenue Estimates
ConforMIS (CFMS) delivered earnings and revenue surprises of -55.56% and -13.04%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Conformis Reports First Quarter 2020 Financial Results
BILLERICA, Mass., May 11, 2020 -- Conformis, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop,.
- GlobeNewswire
Conformis to Host First Quarter 2020 Financial Results Webcast on May 11, 2020
BILLERICA, Mass., May 05, 2020 -- Conformis, Inc. (NASDAQ: CFMS) announced today that it will host a webcast and conference call on Monday, May 11, 2020, at 4:30 p.m. Eastern.
- GuruFocus.com
Covid-19 Hurting Sales of Medtech Companies
With hospitals devoting nearly all their efforts to deal with the pandemic, elective procedures are being put on the backburner Continue reading...
- American City Business Journals
Cambridge biotech to return its PPP loan
A Cambridge startup that already had $147 million in its pocket at the end of last year is returning the Paycheck Protection Program loan it received following nationwide criticism of how the funds were awarded.
- GlobeNewswire
Conformis Announces Return to Work of Furloughed Employees
Conformis, Inc. (CFMS) announced today that, due in large part to a loan made available to the Company under the Paycheck Protection Program (“PPP Loan”) offered by the U.S. Small Business Administration to qualified small businesses in response to the coronavirus (COVID-19) pandemic and the economic harm done to the Company’s business, the Company has accelerated its plan to return to full-time employment the vast majority of those employees who were furloughed on March 23, 2020. With the exception of a few employees who have separated from the Company in the normal course of business, the Company expects most of the furloughed employees to return to active employment as early as April 27, 2020.
- GlobeNewswire
Conformis Receives $4.7 Million under the Paycheck Protection Program
Conformis, Inc. (CFMS) today announced that on April 17, 2020 the Company entered into a $4,719,800 promissory note with East West Bank (EWBC) under the Paycheck Protection Program (“PPP”) offered by the U.S. Small Business Administration (the "SBA") to mitigate the negative financial and operational impacts of the coronavirus (COVID-19) pandemic. In response to the coronavirus (COVID-19) pandemic, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) authorizes the SBA to make available low-interest rate loans to qualified small businesses under the PPP. According to the terms of the PPP, all or a portion of the loan may be fully forgiven if the funds are used for payroll costs (and at least 75% of the forgiven amount must have been used for payroll), interest on certain other outstanding debt, rent, and utilities.
- GlobeNewswire
Conformis to Hold Virtual Annual Meeting of Stockholders on April 27, 2020
Conformis, Inc. (CFMS) today announced that, due to the public health impact of the novel coronavirus outbreak and governmental restrictions limiting the number of people who may gather together, and to support the health and well-being of its stockholders, employees and communities, its 2020 annual meeting of stockholders, to be held on Monday, April 27, 2020 at 4:30 p.m. Eastern time, has been changed to a virtual meeting. Stockholders will be able to participate in this year’s Annual Meeting only via the virtual meeting. Stockholders are entitled to participate in the Annual Meeting if they were a stockholder at the close of business on February 27, 2020, the record date, or hold a legal proxy for the meeting provided by the stockholder’s bank, broker or nominee as of such record date.
- GlobeNewswire
Conformis Announces Actions to Mitigate COVID-19 Impact
Conformis, Inc. (CFMS), an orthopedic arthroplasty medical technology company, today announced proactive steps it is taking and planning to mitigate the negative financial and operational impacts of the coronavirus (COVID-19) pandemic. “Our core product areas of knee and hip surgery are being impacted in unprecedented ways by COVID-19,” said Mark Augusti, President and Chief Executive Officer. When combined with patients’ desire to self-isolate, we have seen a significant reduction in elective surgeries, including an almost complete shutdown of elective arthroplasty in many major cities across Europe and the United States.
- Thomson Reuters StreetEvents
Edited Transcript of CFMS earnings conference call or presentation 2-Mar-20 9:30pm GMT
Q4 2019 Conformis Inc Earnings Call
- GlobeNewswire
Conformis Reports Fourth Quarter and Year End 2019 Financial Results
BILLERICA, Mass., March 02, 2020 -- Conformis, Inc. (NASDAQ:CFMS), announced today financial results for the fourth quarter and year ended December 31, 2019. Q4 Summary Total.
- Simply Wall St.
Is Conformis (NASDAQ:CFMS) Using Debt Sensibly?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
- GlobeNewswire
Conformis, Inc. to Present at the Cowen 40th Annual Health Care Conference
Conformis, Inc. (CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture, and sell joint replacement implants and instruments that are individually sized and shaped, and which the company refers to as personalized or individualized, to fit each patient’s unique anatomy, announced today that management will present at the Cowen 40th Annual Health Care Conference in Boston. The presentation is being made on Wednesday, March 4, 2020, from 11:20 a.m. to 11:50 a.m. EST at the Boston Marriott Copley Place hotel. Conformis is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture, and sell joint replacement implants and instruments that are individually sized and shaped, which we refer to as personalized, individualized, or sometimes as customized, to fit each patient’s unique anatomy.
- GlobeNewswire
Conformis to Host Fourth Quarter and Fiscal Year 2019 Financial Results Webcast on March 2, 2020
BILLERICA, Mass., Feb. 20, 2020 -- Conformis, Inc. (NASDAQ: CFMS) announced today that it will host a webcast and conference call on Monday, March 2, 2020, at 4:30 p.m. Eastern.
- GlobeNewswire
Conformis iTotal® CR Knee Replacement System Awarded “5A” Rating from the Orthopaedic Data Evaluation Panel in the United Kingdom
Conformis, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture, and sell patient-specific knee and hip joint replacement implants designed to fit each patient’s unique anatomy, today announced that the Orthopaedic Data Evaluation Panel in the United Kingdom (ODEP) (http://www.odep.org.uk) awarded the Conformis iTotal® CR knee replacement system a “5A” rating. The 5A rating is based on strong evidence of implant performance over five years, including low revision rates as indicated in the UK’s National Joint Registry (NJR).
- GlobeNewswire
Conformis Appoints Bob Howe as Chief Financial Officer
Conformis, Inc. (CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture, and sell patient-specific knee and hip joint replacement implants designed to fit each patient's unique anatomy, announced today that the Company has appointed Bob Howe as its new Chief Financial Officer, and Gary Maingot as SVP, Operations. Gary’s operational experience and track record of driving operational excellence will help us continue to expand our success in driving gross margin improvement.
- GlobeNewswire
Conformis Achieves 100,000 Implant Milestone for Patient-Specific Knee Replacement Technology
Conformis, Inc. (CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell patient-specific knee and hip joint replacement implants designed to fit each patient's unique anatomy, announced today that the Company has achieved the milestone of 100,000 knee joint replacement implants manufactured and sold in the U.S. “We are very pleased to announce this tremendous milestone for personalized joint replacement implant treatments,” said Mark Augusti, President and Chief Executive Officer. Implants designed specifically for each patient enable efficient surgery and higher levels of patient satisfaction versus standard ‘off-the-shelf’ implants.
- GlobeNewswire
Conformis Reports Preliminary Fourth Quarter and Year-End 2019 Revenue Results
Conformis, Inc. (CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants designed to fit each patient’s unique anatomy, today announced preliminary, unaudited, revenue results for the fourth quarter and the year ended December 31, 2019.
- Simply Wall St.
Did You Miss Conformis's (NASDAQ:CFMS) Whopping 341% Share Price Gain?
It hasn't been the best quarter for Conformis, Inc. (NASDAQ:CFMS) shareholders, since the share price has fallen 29...
- Insider Monkey
Hedge Funds Are Buying ConforMIS, Inc. (CFMS)
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed in recent years. However, hedge funds are generally partially hedged and aim at […]
- Zacks
5 Stocks That Pushed Russell 2000 ETF Higher
Inside the best performing stocks of the Russell 2000 ETF.
- GlobeNewswire
Conformis Announces FDA Clearance and Full Commercial Launch of Next Generation Hip System at the 2019 AAHKS Conference
Conformis, Inc. (CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture, and sell patient-specific arthroplasty joint replacement implants designed to fit each patient’s unique anatomy, today announced FDA clearance of the Company’s next generation Conformis Hip System. The Company will be featuring the new 3D-designed Conformis Hip System as a key technology focus at the 2019 American Academy of Hip and Knee Surgeons annual conference November 7–10, 2019 in Dallas, TX. Conformis previously announced the Company’s first hip surgeries started in July 2018 during its limited launch of the Conformis Hip System.
